| Summary: | 碩士 === 經國管理暨健康學院 === 健康產業管理研究所 === 102 === Aims:The major recent advance in CHC treatment has been the invention of combination therapy with pegylated IFN plus ribavirin. Despite the efficacy, it is sometimes accompanied by side effects that may lead to compromised medical adherence and early termination of therapy. To date, there has not been any published research focusing on which subpopulations are linked to premature withdrawal of therapy.
Materials and Methods:We designed this retrospective study to investigate this issue. A total of 417 consecutive age over 50 y/o’ CHC patients who treated with pegylated IFN α-2b plus ribavirin were enrolled. The mean age was 63.1y/o (range: 50-80) and the mean HCV RNA level was 2.57 ± 4.79 ×106 IU/mL。According to NHI pilot scheme provides medical treatment by a specialist hospital in the digestive system. The object is to meet the conditions of chronic hepatitis C in Taiwan previously untreated patients. Subjects after 24 weeks of treatment, the treatment should be considered to keep track of the end of 24 weeks. A retrospective study of statistics in elderly patients layer treated with therapy for early termination of factors related。
Conclusion:Overall treatment respone of Elderly (over 70 years of age) and liver cirrhosis is the major factor, but if follow the doctor's orders and dose adherence 80/80/80 rule ,it’s still can improve the SVR。
|
|---|
